HomeCompareACGN vs NNN

ACGN vs NNN: Dividend Comparison 2026

ACGN yields 519.62% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACGN wins by $82785.62M in total portfolio value
10 years
ACGN
ACGN
● Live price
519.62%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82785.64M
Annual income
$60,051,464,507.48
Full ACGN calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — ACGN vs NNN

📍 ACGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACGNNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACGN + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACGN pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACGN
Annual income on $10K today (after 15% tax)
$44,167.32/yr
After 10yr DRIP, annual income (after tax)
$51,043,744,831.36/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, ACGN beats the other by $51,043,742,589.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACGN + NNN for your $10,000?

ACGN: 50%NNN: 50%
100% NNN50/50100% ACGN
Portfolio after 10yr
$41392.84M
Annual income
$30,025,733,572.45/yr
Blended yield
72.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ACGN
No analyst data
Altman Z
-10.8
Piotroski
3/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACGN buys
0
NNN buys
0
No recent congressional trades found for ACGN or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACGNNNN
Forward yield519.62%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$82785.64M$25.6K
Annual income after 10y$60,051,464,507.48$2,637.42
Total dividends collected$80827.26M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ACGN vs NNN ($10,000, DRIP)

YearACGN PortfolioACGN Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$62,662$51,961.55$10,737$617.02+$51.9KACGN
2$371,346$304,298.23$11,577$710.93+$359.8KACGN
3$2,082,703$1,685,362.72$12,538$822.59+$2.07MACGN
4$11,062,507$8,834,014.38$13,645$956.06+$11.05MACGN
5$55,690,004$43,853,122.08$14,925$1,116.51+$55.68MACGN
6$265,907,885$206,319,580.72$16,415$1,310.57+$265.89MACGN
7$1,205,205,519$920,684,081.82$18,158$1,546.77+$1205.19MACGN
8$5,189,499,372$3,899,929,466.64$20,213$1,836.20+$5189.48MACGN
9$21,246,897,259$15,694,132,931.16$22,649$2,193.37+$21246.87MACGN
10$82,785,644,575$60,051,464,507.48$25,558$2,637.42+$82785.62MACGN

ACGN vs NNN: Complete Analysis 2026

ACGNStock

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Full ACGN Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ACGN vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACGN vs SCHDACGN vs JEPIACGN vs OACGN vs KOACGN vs MAINACGN vs ADCACGN vs EPRTACGN vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.